Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-02-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于公司核心技术人员职务调整的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the adjustment of a core technical personnel's position within the company, specifically the departure of Dr. Yong Ben from the role of Chief Medical Officer of Immuno-Oncology and the appointment of his successor. It details the personnel change, impact on the company, confidentiality agreements, and the company's internal measures. There is no financial data, no mention of financial results, no regulatory filings of financial nature, no voting results, no capital changes, and no legal proceedings. The document focuses on management-level personnel changes, specifically core technical staff, which aligns with announcements about changes in senior management or board members. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3092 characters, which is relatively short but contains substantive information about management changes rather than just an announcement of a report publication or certification. Hence, it is not RPA or RNS.
2022-02-11 Chinese
中国国际金融股份有限公司、高盛高华证券有限责任公司关于百济神州有限公司免疫肿瘤学首席医学官暨核心技术人员职务调整的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed verification opinion from joint sponsors regarding the adjustment of a key technical personnel position (Chief Medical Officer of Immuno-Oncology) at BeiGene, a company listed on the STAR Market (科创板). It discusses the personnel change, impact on the company, confidentiality agreements, shareholding, and the sponsors' due diligence and conclusion. There is no financial data, no earnings or annual report content, no voting results, no legal proceedings, no capital changes, and no presentation slides. The document is a regulatory announcement related to management personnel changes, specifically about a core technical officer's role adjustment and its impact. This fits best under Board/Management Information (MANG) as it concerns senior management changes and related disclosures. The document length is 3371 characters, which is relatively short but contains substantive content about management changes, not just an announcement of a report or certification. Therefore, the classification is MANG with high confidence.
2022-02-11 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly report on changes in the company's share capital and issued shares, including details on stock options and confirmations related to share issuance. It is addressed to the Hong Kong Stock Exchange and includes detailed tables of share movements, stock option plans, and confirmations of compliance with listing rules. The document does not contain financial statements or earnings data, nor is it an announcement of a meeting or voting results. It is a regulatory filing related to share capital changes but does not announce new share issues or capital changes in the form of a separate capital change announcement. Given the detailed share capital and share issuance information, this fits best under the category of Share Issue/Capital Change (SHA). The document length is about 4,828 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is SHA with high confidence.
2022-02-08 Chinese
港股公告：董事名单及其角色与职能
Governance Information Classification · 95% confidence The document lists the members of the board of directors and their roles and committee memberships. It provides detailed information about the board structure and governance committees but does not contain financial data, earnings, or other report content. This matches the description of a Governance Information report, which details the company's internal rules, board structure, and governance practices. The document length is short and focused solely on board and governance information, so it is not an announcement or a brief notice but a governance report.
2022-02-06 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It details share issuance under a share award plan, including dates, share counts, prices, and compliance confirmations. The document is structured as a regulatory disclosure of share capital changes rather than a full financial report or announcement of a meeting or vote. It is not an annual or interim report, earnings release, or management discussion. The document length is under 5,000 characters and contains detailed share issuance data, fitting the category of Share Issue/Capital Change announcements. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2022-02-06 Chinese
港股公告：授出购股权
Remuneration Information Classification · 95% confidence The document is a formal announcement regarding the grant of share options under the 2016 Option and Incentive Plan by BeiGene, Ltd. It details the number of options granted, exercise price, vesting schedule, and other terms. The document references compliance with listing rules and provides definitions related to the share option plan. It is not a financial report, earnings release, or management discussion. It is also not a proxy statement or AGM material. The content focuses on the issuance of share options to employees, which is a form of remuneration information. The document is relatively short (2202 characters) and is a specific announcement about share-based compensation. Therefore, the most appropriate classification is Remuneration Information (DEF 14A).
2022-02-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.